Physician profile
Sajive Aleyas
NPI 1225106016
$25,979.98
in general payments reported to CMS, 2019-2025
32 companies · $335 in 2025
The $335 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,778 · 2020: $1,940 · 2021: $8,351 · 2022: $3,633 · 2023: $3,916 · 2024: $3,026 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Travel and Lodging: $1,855 · Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Travel and Lodging | $1,854.86 |
| Food and Beverage | $922.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,466.61 | 2019-2025 | Ion, Da Vinci Surgical System |
| Pulmonx Corporation | $7,754.78 | 2019-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Astrazeneca Pharmaceuticals Lp | $2,400.57 | 2019-2025 | Tagrisso |
| Ethicon INC. | $2,097.78 | 2022 | |
| Covidien Lp | $1,258.67 | 2019-2020 | |
| Veran Medical Technologies, INC. | $1,086.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $780.28 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Galvanize Therapeutics, INC | $401.71 | 2024-2025 | Aliya System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.49 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $207.78 | 2021-2022 | |
| Getinge USA Sales, LLC | $169.00 | 2019 | |
| Insmed, INC. | $140.94 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.81 | 2021-2022 | |
| Circassia INC. | $101.29 | 2019-2020 | |
| United Therapeutics Corporation | $88.99 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $87.45 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $83.61 | 2021-2022 | |
| Baxter Healthcare | $80.93 | 2022 | |
| Genzyme Corporation | $70.00 | 2021-2022 | |
| Boston Scientific Corporation | $57.86 | 2020-2021 | |
| Pinnacle Biologics, INC | $56.92 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $47.27 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.49 | 2021-2022 | |
| Amgen INC. | $39.05 | 2022 | |
| Mallinckrodt Enterprises LLC | $25.35 | 2019 | |
| Advanced Respiratory, INC | $20.34 | 2021 | |
| Pfizer INC. | $19.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.49 | 2019 | |
| Sanofi Pasteur INC. | $15.48 | 2020 | |
| Nabriva Therapeutics, Plc | $15.21 | 2021 | |
| Vapotherm INC | $13.14 | 2022 | |
| Erbe USA INC | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajive Aleyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.